{
  "nctId": "NCT02191579",
  "briefTitle": "Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults",
  "officialTitle": "A Multicenter, Prospective, Randomized, Open-label Study to Compare the Efficacy, Safety, and Tolerability of BOTOX® and Topiramate for Headache Prophylaxis in Adults With Chronic Migraine",
  "protocolDocument": {
    "nctId": "NCT02191579",
    "filename": "Prot_001.pdf",
    "label": "Study Protocol",
    "date": "2014-05-27",
    "uploadDate": "2018-05-07T17:37",
    "size": 1262322,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02191579/document/Prot_001.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 282,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2014-08-05",
    "completionDate": "2017-09-01",
    "primaryCompletionDate": "2017-05-09",
    "firstSubmitDate": "2014-07-14",
    "firstPostDate": "2014-07-16"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* History of chronic migraine\n* More than 15 headache days in a 28 day period (headaches that last more than 4 hours and/or require treatment with prescription medication).\n\nExclusion Criteria:\n\n* Taking opioid-containing products for acute headache treatment more than 8 days during a 28-day period\n* Previous treatment with botulinum toxin of any serotype for any reason\n* Previous treatment with topiramate\n* On a ketogenic diet (high in fat, low in carbohydrates)\n* History of acute myopia or increased intraocular pressure\n* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis or any other significant disease that might interfere with neuromuscular function\n* Acupuncture, transcutaneous electrical stimulation (TENS), cranial traction, dental splints for headache, or injection of anesthetics/steroids in the 4 weeks prior to screening.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants With a ≥ 50% Decrease From Baseline in the Frequency of Headache Days",
        "description": "Participants recorded their headaches in a daily e-diary. A headache day was defined as a calendar day (00:00 to 23:59) with 4 or more hours of headache and/or headache of any duration with the use of migraine-specific acute headache medication(s). The number of headache days over the 28-day period was counted. The percentage of participants with a ≥ 50% decrease in headache days in the 28-day period prior to Week 32 relative to Baseline (28-day period prior to Day 1) is reported.",
        "timeFrame": "Baseline (First 28 days from Screening) to the last 28-day period ending with Week 32"
      }
    ],
    "secondary": [
      {
        "measure": "Change From Baseline in the Frequency of Headache Days Per 28-day Period",
        "description": "Participants recorded their headaches in a daily e-diary. A headache day was defined as a calendar day (00:00 to 23:59) with 4 or more hours of headache and/or headache of any duration with the use of migraine-specific acute headache medication(s). The number of headache days over the 28-day period was counted. A negative change from Baseline (less headache days) indicates improvement.",
        "timeFrame": "Baseline (First 28 days from Screening) to the last 28-day period ending with Week 32"
      },
      {
        "measure": "Change From Baseline in Headache Impact Test (HIT-6) Total Score",
        "description": "The HIT-6 is a valid disease-targeted measure used to assess the impact of headaches, comprised of 6 items that assess pain, role functioning, social functioning, cognitive functioning, vitality, and psychological distress. A total score is created by summingacross all items, and ranges from 36 (no impact) to 78 (severe impact) reflecting a \"best to worst\" scoring.\n\nA negative change from Baseline (a lower score) indicates improvement.",
        "timeFrame": "Baseline (Day 1) to the last 28-day period ending with Week 30"
      },
      {
        "measure": "Percentage of Participants With a ≥ 70% Decrease From Baseline in the Frequency of Headache Days",
        "description": "Participants recorded their headaches in a daily e-diary. A headache day was defined as a calendar day (00:00 to 23:59) with 4 or more hours of headache and/or headache of any duration with the use of migraine-specific acute headache medication(s). The number of headache days over the 28-day period was counted. The percentage of participants with a ≥ 70% decrease in headache days in the 28-day period prior to Week 32 relative to Baseline (28-day period prior to Day 1) is reported.",
        "timeFrame": "Baseline (First 28 days from Screening) to the last 28-day period ending with Week 32"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 3,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 39,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:54.720Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}